Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

X
Trial Profile

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Mast Cell Leukemia; Systemic mastocytosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHFINDER
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 30 May 2024 According to a Blueprint Medicines media release, data from this trial will be presented at European Hematology Association 2024 (EHA24) Hybrid Congress
    • 01 Aug 2023 Planned End Date changed from 1 Jan 2026 to 31 Jan 2026.
    • 01 Aug 2023 Planned primary completion date changed from 1 Jan 2026 to 31 Jan 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top